timothy sykes logo
Will Exact Sciences Continue Its Surge? Thumbnail
G Google News

Will Exact Sciences Continue Its Surge?

MATT MONACO•UPDATED NOV. 19, 2025, 5:04 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Exact Sciences Corporation’s stocks have been trading up by 24.07 percent after FDA approval of groundbreaking cancer test.

Bold Moves: Recent Developments at Exact Sciences

  • The Oncoguard Liver blood test from Exact Sciences has demonstrated superior capabilities over traditional ultrasound, boosting the chances for early liver cancer detection and potentially improving survival rates.
  • In the third quarter, Exact Sciences saw a 20% rise in revenue and introduced Cancerguard®, leading to a revision of their full-year 2025 forecast.
  • The company has achieved the antitrust waiting period expiration for a license with Freenome, paving the way to expand its cancer screening leadership with Freenome’s blood tests.
  • Analysts from Baird and Piper Sandler have increased their price targets for Exact Sciences to $88 and $80, respectively, following impressive quarterly performance.
  • Q3 earnings exceeded expectations with $850.74M in revenue and $0.28 EPS, beating forecasts—the positive results led to an increase in financial guidance for 2025.

Candlestick Chart

Live Update At 17:04:00 EST: On Wednesday, November 19, 2025 Exact Sciences Corporation stock [NASDAQ: EXAS] is trending up by 24.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Exact Sciences Financial Health: A Quick Snapshot

When embarking on the world of penny stock trading, it’s important to keep the right mindset. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Understanding that losses are part of the process can help traders refine their techniques and stay motivated. By viewing mistakes as opportunities for growth, traders can develop a more resilient approach to the market, ultimately leading to greater success over time.

Exact Sciences recently reported strong financial metrics, reflecting growth and stability. In the latest quarter, Exact Sciences reported a significant uptick in revenue, jumping 20%, suggesting effective strategies in place. Their Oncoguard Liver test has outperformed traditional methods, promising improved patient outcomes. With the success of their Altus study, the diagnostic capability has been enhanced, which is a critical advantage in healthcare.

Their revenue reached just over $850M in Q3 2025, way beyond analysts’ expectations. This beating of consensus is a clear indicator of the company’s vitality. Despite their steady gains, challenges like profitability margins remain. For instance, their negative EBIT margin of 33.7% reflects ongoing transformation costs. However, their gross margin of 68.2% shines, underlying substantial profitability potential once the transition period concludes.

Looking at key ratios, the current and quick ratios pin Exact Sciences as having a healthy liquidity profile. A current ratio of 2.9 demonstrates ample resources to cover liabilities. Yet, their leverage, with total debt to equity at 1.02, suggests they are treading carefully to manage long-term obligations versus equity.

More Breaking News

From a cash flow perspective, Exact Sciences displays an investing cash flow challenge, indicating long-term capital deployment for innovation and growth. However, an upswing in operating cash flow merits focus. This reflects a positive cash cycle generated through operational efficacy, highlighting sound management strategies.

The Impact of Recent News on the Market

Recent strategic developments at Exact Sciences hint at pivotal implications for the market. With the introduction of Cancerguard® and superior liver tests, they are capturing substantial market share in cancer diagnostics. The results of the Altus study further solidify their position, demonstrating successful R&D outcomes. In essence, these medical breakthroughs not only have the potential to improve life expectancies but also set the stage for sustained revenue growth in upcoming periods.

Exact Sciences’ Q3 report, marked by an earnings surprise, uplifted analysts’ sentiments, reflected in upgraded target prices by various financial institutions. The extended guidance for Q4 2025 corroborates their bullish outlook catalyzed by effective product endeavors. These positive signals resonate well with investors, likely fostering enhanced stock performance.

Additionally, strategic alliances, like the exclusive license with Freenome, underscore their commitment to lead in innovative diagnostics. Such moves represent a calculated venture into broader, technologically advanced cancer screening avenues, likely to reverberate through market valuations positively.

Conclusion: A Path Forward for Investors

As the narrative unfolds at Exact Sciences, its blend of R&D victories and market resilience plays a crucial role. The surge in stock value, driven by ground-breaking test outcomes and robust earnings, positions them as a key player in diagnostics. The anticipated revenue scaling and market recognition highlight a bright corridor ahead—ensuring traders’ attention is keenly drawn to swift decision-making opportunities. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” This principle underlines the strategic approach needed to navigate the dynamic trading environment around Exact Sciences.

In essence, Exact Sciences crafts a compelling narrative of growth and innovation. Though profitability remains a space for development, their comprehensive market approach positions them on a path that may sustain the upward tick in stock prices. As new developments surface, the key lies in maintaining momentum whilst delivering transformative, life-saving solutions in cancer diagnostics.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”